Purpose Of Review: Cutaneous T cell lymphomas (CTCLs) are comprised of a heterogenous group of non-Hodgkin lymphomas that can be difficult to treat and are often refractory to standard therapies. Mycosis fungoides (MF) and Sezary syndrome (SS) are the most common subtypes, accounting for the majority of CTCLs. There is no standard of care, and no treatments are curative. In this review, we summarize the promising, recently reported data describing novel systemic agents for the management of MF/SS.
Recent Findings: Clinical trials are currently exploring a number of agents, including novel chemotherapies, antibodies and antibody drug conjugates (ADCs), immunotherapy, and cellular therapies. These promising novel agents may expand the treatment landscape for MF/SS.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s11899-024-00746-7 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Advances in Novel Systemic Therapies for the Management of Cutaneous T Cell Lymphoma (CTCL).
Curr Hematol Malig Rep
January 2025
Department of Hematology, Winship Cancer Institute, Atlanta, GA, USA.
Purpose Of Review: Cutaneous T cell lymphomas (CTCLs) are comprised of a heterogenous group of non-Hodgkin lymphomas that can be difficult to treat and are often refractory to standard therapies. Mycosis fungoides (MF) and Sezary syndrome (SS) are the most common subtypes, accounting for the majority of CTCLs. There is no standard of care, and no treatments are curative.
View Article and Find Full Text PDFObjective: To test whether messenger RNA (mRNA) splicing is altered in neutrophils from patients with systemic lupus erythematosus (SLE) and can produce neoantigens.
Methods: RNA sequencing of neutrophils from patients with SLE (n = 15) and healthy donors (n = 12) were analyzed for mRNA splicing using the RiboSplitter pipeline, an event-focused tool based on SplAdder with subsequent translation and protein domain annotation. RNA sequencing from SARS-CoV2-infected individuals was used as an additional comparator.
Comprehensive cost-of-illness analysis of pressure ulcer treatment: A real-world study at a Czech university hospital.
Int Wound J
January 2025
Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
Pressure ulcers (PUs) impose a significant economic burden on healthcare systems, affecting patient quality of life and leading to substantial treatment costs. This study presents a cost-of-illness analysis of PU treatment in hospitalized patients in the Czech Republic, based on real-world clinical data. The analysis was conducted using a comprehensive methodology at a Czech university hospital, involving 304 hospitalizations.
View Article and Find Full Text PDFTransformation fate of bisphenol A in aerobic denitrifying cultures and its coercive mechanism on the nitrogen transformation pathway.
Environ Res
January 2025
State Key Laboratory of Marine Pollution and Department of Chemistry, City University of Hong Kong, Tat Chee Avenue, Kowloon, Hong Kong 999077, China; School of Energy and Environment, City University of Hong Kong, Tat Chee Avenue, Hong Kong Kowloon, 999077, China. Electronic address:
Bisphenol A (BPA) is a commonly used endocrine-disrupting chemical found in high levels in wastewater worldwide. Aerobic denitrification is a promising alternative to conventional nitrogen removal processes. However, the effects of BPA on this novel nitrogen removal process have rarely been reported.
View Article and Find Full Text PDFIntranasal administration of stem cell-derived exosome alleviates cognitive impairment against subarachnoid hemorrhage.
Exp Neurol
January 2025
Department of Neurosurgery, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
Introduction: Brain damage caused by subarachnoid hemorrhage (SAH) currently lacks effective treatment, leading to stagnation in the improvement of functional outcomes for decades. Recent studies have demonstrated the therapeutic potential of exosomes released from mesenchymal stem cells (MSC), which effectively attenuate neuronal apoptosis and inflammation in neurological diseases. Due to the challenge of systemic dilution associated with intravenous administration, intranasal delivery has emerged as a novel approach for targeting the brain.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!